Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.47 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29715987 | 1.00 | ESR1 (0.51) | ESR1SKP2POLBCYP3A4CYP2D6 | |
| SCHEMBL3406984 | 0.88 | POLB (0.48) | SKP2POLBCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21003290 | 0.86 | SKP2 (0.53) | SKP2POLBCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6829715 | 0.86 | SKP2 (0.53) | SKP2POLBCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9979434 | 0.85 | PLK1 (0.52) | SKP2MEN1KMT2APLK1 | |
| SCHEMBL14831584 | 0.84 | GAA (0.51) | SKP2POLBCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7903540 | 0.83 | ESR1 (0.52) | ESR1POLBCYP3A4CYP2C9MEN1 | |
| SCHEMBL10750344 | 0.83 | CYP4Z1 (0.49) | ESR1KMT2ACYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL12598866 | 0.83 | CA1 (0.50) | SKP2POLBALDH1A1HPGDMETAP2 | |
| SCHEMBL2748823 | 0.83 | CA1 (0.49) | POLBALDH1A1HPGDMETAP2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2954896-A1 | Small molecule inhibitors of the E3 Ligase Skp2 in depression and other diseases | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-16 | — | — | EP | claimed |
| US-20220347277-A1 | Methods to Enhance Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapeutic Products Using Modified Tumor Cells and Modified Dendritic Cells | AIVITA BIOMEDICAL INC (US) | 2022-11-03 | — | — | US | disclosed |
| WO-2021050547-A1 | MITOCHONDRIAL COMPLEX I INHIBITORS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20200230219-A1 | Methods to Enhance Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapeutic Products Using Modified Tumor Cells and Modified Dendritic Cells | AIVITA BIOMEDICAL, INC. | 2020-07-23 | — | — | US | disclosed |
| WO-2018151813-A1 | METHODS TO ENHANCE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS CANCER IMMUNOTHERAPEUTIC PRODUCTS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS | AIVITA BIOMEDICAL, INC. (US) | 2018-08-23 | — | — | WO | disclosed |
| EP-2954896-A1 | Small molecule inhibitors of the E3 Ligase Skp2 in depression and other diseases | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2954896-A1 | Small molecule inhibitors of the E3 Ligase Skp2 in depression and other diseases | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-20090054312-A1 | SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054312-A1 | SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases | CDKN1A, CDK4, CDK2 | ESR1 1987/4885SKP2 6/4885POLB 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.